RT Journal Article
SR Electronic
T1 The clinical effects of vasopressin receptor antagonists in heart failure
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP S24
OP S29
VO 73
IS 6 suppl 2
A1 Gary Francis
A1 Mihai Gheorghiade
YR 2006
UL http://www.ccjm.org/content/73/6_suppl_2/S24.abstract
AB The neurohormone arginine vasopressin (AVP) is a promising target in the treatment of heart failure because AVP promotes congestion and hyponatremia, each of which is associated with poor outcomes. Diuretics are standard therapy for heart failure, but they have several limitations, including worsening renal function and hyponatremia. Blocking AVP leads to effective aquaresis, improvements in hemodynamics and renal function parameters, weight loss, and normalization of serum sodium, without changes in blood pressure or heart rate. In placebo-controlled trials in the inpatient and outpatient setting, the AVP receptor antagonist tolvaptan reduced body weight and edema and normalized serum sodium in patients with heart failure.